AeroPace System
Lungpacer Medical USA, Inc. · Decision date Jan 14, 2026
What did the FDA decide?
FDA records P240012/S004 as a supplement to PMA P240012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jan 14, 2026.
FDA approval order statement
Addition of two suppliers of PCBAs included in the assembly of the Neurostimulation Console and Handheld Controller.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Anesthesiology
- Decision date
- Jan 14, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240012/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- Decision code
- OK30
- Decision date
- Jan 14, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Transvenous temporary phrenic nerve stimulator.
- Applicant
- Lungpacer Medical USA, Inc.
- Product code
- SDL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240012. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240012 · Original PMA
AeroPace System
P240012/S002 · Related supplement
AeroPace System
P240012/S003 · Related supplement
AeroPace System
P240012/S004 received
Application receipt date recorded by FDA.
P240012/S004 · FDA decision
30-Day Notice
P240012/S005 · Related supplement
AeroPace System
P240012/S006 · Related supplement
AeroPace System
P240012/S007 · Related supplement
AeroPace System
P240012/S008 · Related supplement
AeroPace System
Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240012
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
AeroPace SystemP240012 | Lungpacer Medical USA, Inc. | PMA approval | Dec 4, 2024 | FDA |
AeroPace SystemP240012/S002 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 23, 2025 | FDA |
AeroPace SystemP240012/S003 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 29, 2025 | FDA |
AeroPace SystemP240012/S005 | Lungpacer Medical USA, Inc. | PMA supplement | Feb 20, 2026 | FDA |
AeroPace SystemP240012/S006 | Lungpacer Medical USA, Inc. | PMA supplement | Jun 22, 2026 | FDA |
AeroPace SystemP240012/S007 | Lungpacer Medical USA, Inc. | PMA supplement | Jun 22, 2026 | FDA |
AeroPace SystemP240012/S008 | Lungpacer Medical USA, Inc. | PMA supplement | Sep 25, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lungpacer Medical USA, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 260 Sierra Dr., Suite 116, Exton, PA, 19341
Sources and methodology
- Original FDA record: P240012/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




